Abstract
The term “negative” symptoms is most frequently attributed to the neurologist Hughlings Jackson; however, other individuals also attempted to conceptualize this aspect of phenomonology in schizophrenia (Reynolds 1858). Kraepelin (1919) and Bleuler (1950) considered blunted affect and emotional withdrawal as core features of this illness. Though the presence of apathy, anergia, alogia and blunted affect have always been considered as frequent aspects of schizophrenia, they have received varying attention and weight in different eras as criteria for diagnosis. To some extent this reflects the difficulty in reliably defining and measuring them, in contrast to positive symptoms. There is currently a renewed interest in negative symptoms because of their potential value in helping to subclassify patients in ways which might be useful from both a prognostic and pathophysiologic perspective. In addition, increasing efforts to develop antipsychotic compounds either with a broader or novel spectrum of activity have focused more attention on residual and negative symptoms. Since these are the symptoms that may remain most salient after optimal neuroleptic treatment, they contribute enormously to the chronic disability associated with schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Alpert M (1991) Vocal acquistic correlates of flat affect: contrast with other negative signs and depression. Schizophr Res 4: 247–248
Andreasen NC (1983) The scale for the assessment of negative symptoms (SANS). University of Iowa Press, Iowa
Andreasen NC, Olsen S (1982) Negative and positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789–793
Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology (Berl) 72: 17–19
Barnes TRE, Liddle PF (1990) The symptoms of chronic schizophrenia. Br J Psychiatry 157: 558–561
Bleuler E (1950) Dementia praecox or the group of schizophrenias. International Universities Press, New York
Brier A, Wolkowitz OM, Doran AR et al. (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549–1555
Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology (Berl) 91: 104–108
Carpenter WT Jr, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452
Cesarec Z, Nyman AK (1985) Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 71: 523–528
Chouinard G, Annable L (1979) Pimozide in the treatment of acute schizophrenia. Paper presented at the American Psychiatric Association Annual Meeting, Chicago
Crow TJ (1980) Molecular pathology of schizophrenia: more than one dimension of pathology? Br Med J 143: 66–68
Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486
Eccleston D, Fairbain AF, Hassanyeh F et al. (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147: 623–630
Gerlach J, Luhdrof K (1975) The effect of L-dopa on young patients with simple schizophrenia treated with neuroleptic drugs. Psychopharmacology (Berl) 44: 105–110
Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456
Haas S, Beckmann H (1982) Pimozide versus haloperidol in acute schizophrenia: A double-blind controlled study. Pharmacopsychiatry 15: 70–74
Inanaga K, Inouee K, Tachibana H et al. (1972) Effect of L-dopa in schizophrenia. Folia Psychiatr Neurol Jn 26: 145–157
Kane J, Rifkin A, Woerner M et al. (1983) Low dose neuroleptic treatment of outpatient schizophrenics: preliminary results for relapse rates. Arch Gen Psychiatry 4: 893–896
Kane J, Honifgeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796
Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardization. Br J Psychiatry (Suppl) 7: 59–65
Kolivakis T, Azian H, Kingstone E (1974) A double-blind comparison of pimozide and chlorpromazine in the maintenance of chronic schizophrenic patients. Curr Ther Res 16: 998–1004
Kraepelin E (1919) Dementia praecox and paraphrenia. Krieger, New York
Krawiecka M, Goldberg D, Vaughan MA (1977) Standardized psychiatric assessment for rating chronic patients. Acta Psychiatr Scand 55: 299–308
Lapierre YD (1978) A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry 135: 956–959
Lapierre YD, Lavallee J (1975) Pimozide and the social behaviors of schizophrenics. Curr Ther Res 18: 181–188
Liddle PF (1987) The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry 151: 145–151
Lieberman J A, Jody D, Alvir JMJ, Borenstein M, Mayerhoff DI (1991) Negative symptoms in schizophrenia: relationship to positive symptoms and outcome. In: Maneros A, Andreasen NC, Tsuang M (eds) Netative Versus Positive Schizophrenia. Springer, Berlin Heidelberg New York, pp 109–125
Lindenmayer JP, Kay SR (1989) Depression, affect and negative symptoms in schizophrenia. Br J Psychiatry 155 (Suppl): 108–114
Lindenmayer JP, Kay SR, Friedman C (1986) Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. Compr Psychiatry 27: 276–286
Overall JE, Gorham D (1964) The brief psychiatric rating scale. Psychol Rep 10: 799–812
Reynolds JR (1858) On the pathology of convulsions with special reference to those of children. Liverpool Med Chir J 2: 1–14
Rifkin A, Quitkin F, Kane JM et al. (1978) Are prophylactic antiparkinsonian drugs necessary? A controlled study of procyclidine withdrawal. Arch Gen Psychiatry 35: 483–389
Sheppard GP (1979) High dose propranolol in schizophrenia. Br J Psychiatry 134: 47–476
Siris SG, Adan F, Cohen M et al. (1988) Post-psychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145: 1532–1537
Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988) Post-psychotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 145: 1532–1537
Van Kammen DP, Boronow JJ (1988) Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 3: 111–121
Ventura J, Nuechterlein K, Green M, Mintz J (1991) Characterization of positive and negative symptoms in the early course of schizophrenia. Schizophr Research 4: 270–271
Wolkowitz OM, Pickar D, Doran AR et al. (1986) Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 143: 85–87
Wolkowitz OM, Turetsky N, Reus VI et al. (1991) Benzodiazepine responsivity in schizophrenia. Schizophr Res 4: 296
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kane, J.M. (1993). Residual and Negative Symptoms in Treatment with Neuroleptics. In: Gram, L.F., Balant, L.P., Meltzer, H.Y., Dahl, S.G. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 10. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78010-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-78010-3_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78012-7
Online ISBN: 978-3-642-78010-3
eBook Packages: Springer Book Archive